dumbcritic
@dumbcritic
Topics: 29 / Replies: 96
Reply
RE: A potentially targetable Achilles' heel of cancer

The median starting dose from the two trials by Achilles was 15M cells, but with some changes to the ex vivo expansion, the highest dose level tested ...

3 years ago
Topic
Replies: 0
Views: 1087
Reply
RE: Update on POH for GMB: Promising results from NeOnc Technologies, Inc.

The PhII is ongoing, with data for both endpoints expected this year. Also, a new paper. From it: ''Intranasal NEO100 was well tolerated at all ...

3 years ago
Forum
Reply
RE: A potentially targetable Achilles' heel of cancer

The IDSMC (Independent Data and Safety Monitoring Committee) has completed its first review of the ongoing, PhI/II CHIRON (advanced NSCLC) and THETIS ...

3 years ago
Reply
RE: 3BP may advance to clinical trials with NewGLAB Co.

@daniel Thanks. Hopefully, there will be some more case reports, or a series published in the (near) future. As for development, I hope they have th...

3 years ago
Reply
RE: Hydroxychloroquine

In this paper, it was shown that inhibition of autophagy enhanced sensitivity to dual immune checkpoint inhibition (anti-CTLA-4 plus anti-PD-1)/p> ...

3 years ago
Reply
RE: A potentially targetable Achilles' heel of cancer

PACT Pharma expects clinical data from ten patients this quarter, plus additional as the year goes on (around six per quarter). The goal is to elucida...

3 years ago
Reply
RE: Oncolytic viruses

Daiichi Sankyo has submitted an IND/span> Also, Replimune has dosed the first patient with RP3/p>

3 years ago
Reply
RE: Devimistat

An oral form of devimistat (RFL-618) is in development, as are three second generation compounds (RFL-5800/5990/6520). INDs are expected to be filed e...

3 years ago
Topic
Replies: 2
Views: 877
Topic
Replies: 0
Views: 1216
Topic
4 years ago
Forum
Replies: 0
Views: 1548
Reply
RE: Vit B3 analogue (nicotinamide riboside)

A new preclinical study in pancreatic combining it with gemcitabine/p>

4 years ago
Topic
4 years ago
Replies: 1
Views: 552
Topic
4 years ago
Replies: 0
Views: 719
Reply
RE: Oncolytic viruses

An RP2 update. The three responses are now two PRs and one CR, but denominator is nine patients (not six), for a 33% (not 50% originally) ORR.

4 years ago
Reply
RE: Combo Metformin And Syrosingopine!!!! Looks Awesome!

John, I'm sorry to hear of the loss of your wife. My deepest sympathies to you (and family).

4 years ago
Topic
4 years ago
Replies: 0
Views: 730
Reply
RE: Oncolytic viruses

The overall response rate (patients with cutaneous squamous cell carcinoma with at least eight weeks of follow-up) for RP1 plus cemiplimab has increas...

4 years ago
Topic
Replies: 1
Views: 6923
Reply
RE: CD47

Trillium Therapeutics has update results from early-stage dose-escalation studies of top candidates TTI-621 and TTI-622 [1]. TTI-621 (SIRPa-IgG1 fus...

4 years ago
Reply
RE: CD47

Encouraging data on Gilead's Magrolimab in MDS and AML [1]. Here is a link to the pivotal trial in MDS [2] and another in AML (this is not pivotal, bu...

4 years ago
Reply
RE: Oxaloacetate

@jcancom No problem. Speaking of OVs, Replimmune's lead product (RP1) is currently in three registration-directed clinical trials and if all goes to p...

4 years ago
Reply
RE: Oxaloacetate

@daniel Thanks. I know a few companies on Amazon (the U.S. site) claim to sell it, but I don't know if they are trustworthy, and even if so it could b...

4 years ago
Topic
4 years ago
Replies: 0
Views: 951
Topic
4 years ago
Replies: 5
Views: 1933
Reply
RE: Devimistat

The drug with gemcitabine and nab-paclitaxel [1], fully enrolled in one pivotal trial [2], and past the midpoint in another (again, pivotal) [3]. ...

4 years ago
Reply
RE: OXPHOS inhibitors

Preclinical data (IACS-010759)/span>

4 years ago
Reply
RE: A potentially targetable Achilles' heel of cancer

One group has published that certain tumour-reactive CD8+ T-cells are CD39/CD103 double positive [1]. These cells have been found in many solid tumour...

4 years ago
Reply
RE: OXPHOS inhibitors

New data on IM156/p>

4 years ago
Page 2 / 5